Abstract: A constant release rate indomethacin formulation in tablet unit dosage form, said tablet comprising an intimate admixture of from 50 to 200 mg of indomethacin, from about 1.7 to 3.7 weight percent of a slow-dissolving, water-insoluble cellulose derivative, from about 1.5 to 5.0 weight percent of a tabletting disintegrant, and from about 40 to 80 weight percent of a pharmaceutically acceptable bulking agent or diluent.
Abstract: A constant order release rate solid oral dosage formulation of propranolol or a pharmaceutically acceptable salt thereof, said formulation comprising: a therapeutically effective amount of propranolol or a pharmaceutically acceptable salt; from about 0.5 to 6.0 weight percent of an acid-retardant or hydrophobic cellulose derivative; from about 2.5 to 35 weight percent of a hydrogenated vegetable oil: from about 1 to 20 weight percent of an acrylic acid polymer; from about 0.5 to 4.0 weight percent of fumed silicon dioxide and from about 0.4 to 3.0 percent of a lubricant.
Abstract: A constant order release rate solid oral dosage formulation of hydralazine or a pharmaceutically acceptable salt thereof, said formulation comprising: a therapeutically effective amount of hydralazine or a pharmaceutically acceptable salt; from about 0.5 to 6.0 weight percent of an acid-retardant or hydrophobic cellulose derivative; from about 2.5 to 35 weight percent of a hydrogenated vegetable oil: from about 1 to 20 weight percent of an acrylic acid polymer; from about 0.5 to 4.0 weight percent of fumed silicon dioxide and from about 0.4 to 3.0 percent of a lubricant.
Abstract: A constant order release rate solid oral dosage formulation of quinidine or a pharmaceutically acceptable salt thereof, said formulation comprising: a therapeutically effective amount of quinidine or a pharmaceutically acceptable salt; from about 0.5 to 6.0 weight percent of an acid-retardant or hydrophobic cellulose derivative; from about 2.5 to 35 weight percent of a hydrogenated vegetable oil: from about 1 to 20 weight percent of an acrylic acid polymer; from about 0.5 to 4.0 weight percent of fumed silicon dioxide and from about 0.4 to 3.0 percent of a lubricant.
Abstract: A constant release aspirin tablet comprising from 85-95 weight percent of aspirin, from 1.5-5 weight percent of microcrystalline cellulose, from 1-10 weight percent of cellulose acetate phthalate, from 0.75-4 weight percent of a plasticizer, from 0.75-5 weight percent of corn starch, and from 0.5 to 2 percent of a lubricant.
Abstract: A constant order release rate solid oral dosage formulation of verapamil or a pharmaceutically acceptable salt thereof, said formulation comprising: a therapeutically effective amount of verapamil; from about 0.5 to 6.0 weight percent of an acid-retardant or hydrophobic cellulose derivative; from about 2.5 to 35 weight percent of a hydrogenated vegetable oil: from about 1 to 20 weight percent of an acrylic acid polymer; from about 0.5 to 4.0 weight percent of fumed silicon dioxide and from about 0.4 to 3.0 percent of a lubricant.
Abstract: A constant order release aspirin tablet comprising aspirin, from 0.5 to 10 weight percent of a hydrogenated vegetable oil and from 0.5 to 7 weight percent of a saccharide selected from the group consisting of lactose, sucrose, dextrose fructose and maltose. The aspirin tablet is administered once or twice a day for the chronic treatment of arthritis, and has substantially lessened gastrointestinal side effects.